Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks Investment Research  from a “buy” rating to a “hold” score in a research note issued to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on uncovering and also establishing little particle medicine prospects to treat cancer. The Firm‘s products under various phases of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research analysts also recently talked about the business. Noble Financial reissued a “purchase” score as well as released a $11.00 cost goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day moving average price of $2.90 and also a two-hundred day moving typical cost of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an unfavorable web margin of 8,294.27%. The firm had income of $0.06 million during the quarter, compared to the agreement quote of $0.06 million. During the same quarter in the previous year, the company uploaded ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will upload -1.18 EPS for the current year.

A number of hedge funds have actually just recently dealt shares of ONTX. GSA Capital Allies LLP purchased a brand-new placement in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Resources Administration LP purchased a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC got a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP bought a new setting in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and other institutional financiers own 13.36% of the firm’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which takes part in the recognition as well as advancement of oncology therapeutics. It focuses on discovering as well as developing tiny molecule medication prospects to deal with cancer cells. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For more details about research offerings from Zacks Investment Research, go to Zacks.com.

This instantaneous information alert was generated by narrative scientific research technology as well as monetary information from Market in order to give readers with the fastest as well as most precise reporting. This story was assessed by Market’s editorial group before magazine. 



Before you think about Onconova Therapeutics, you’ll want to hear this.

Market keeps an eye on Wall Street’s premier and best executing research experts as well as the stocks they advise to their clients on a daily basis. Market has actually identified the five stocks that top experts are quietly whispering to their customers to acquire currently prior to the more comprehensive market catches on … and Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” rating amongst experts, top-rated analysts believe these five stocks are better buys.